Armed with a PhI can­cer drug from Bay­er, an Ac­er­ta founder breaks cov­er and writes him­self a $60M blank check deal

Ahmed Hamdy has been busy.

This morn­ing Hamdy — one of the key co-founders at Ac­er­ta — jumped out of stealth mode with a new biotech that has a small but sig­nif­i­cant pipeline, in­clud­ing one can­cer drug in Phase I de­vel­op­ment. And he’s vault­ed ful­ly in­to the open, leap­ing on­to Wall Street through a SPAC that leaves the com­pa­ny with $60 mil­lion in its cof­fers to do some­thing with its drugs.

Now they’ll start trad­ing as $VINC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER